European Pharmaceutical Review
OCTOBER 13, 2022
Scientists at MIT have demonstrated that a novel robotic capsule could potentially replace conventional biologic injection methods by tunnelling through the intestinal mucus barrier to deliver insulin. The research, published in the journal Science Robotics described how the new drug delivery system can transport large protein and small-molecule drugs, like vancomycin, an antibiotic peptide.
MedCity News
OCTOBER 13, 2022
Providence issued a response to a letter sent by Sen. Patty Murray of Washington, in which she demanded the health system answer questions about its alleged efforts to aggressively bill patients who qualified for free or discounted care. The response denied that Providence aggressively pursued its poorest patients for medical debt, asserting that its “commitment to those in need has never been stronger.”.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Star OUTiCO
OCTOBER 13, 2022
Star OUTiCO, as part of the Uniphar Group Commercial & Clinical division, is getting ready for this year’s group Unity for Hope initiative, raising vital funds for seven cancer charities across Ireland, the UK, US, and Australia. Launching on Monday 24 th October, Unity for Hope will see companies spread across the Uniphar Group aim to raise an impressive €100k – to be matched by Uniphar up to a further €100k, by reaching 15,000,000 steps – or equivalent cycle rotations – d
MedCity News
OCTOBER 13, 2022
Gilead Sciences is a leader in the field of virology treatments. As VP of clinical research for hepatitis, respiratory and emerging viruses at Gilead, Anu Osinusi talked about the pharma company’s work in HIV and hepatitis and how her personal background informed her team’s work in developing a Covid-19 treatment.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Medgadget
OCTOBER 13, 2022
Researchers at Carnegie Mellon University have used a nanoscale 3D printing technique that allows them to customize the microelectrode arrays used for brain computer interfaces. The approach is called Aerosol Jet 3D printing, and the researchers used it to create three-dimensional microelectrode arrays that can be customized for particular patient needs.
MedCity News
OCTOBER 13, 2022
Should we start treating menopause as a disease condition? In our view, it’s a chronic disease condition that can go beyond two decades for some women, resulting in silent suffering.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
OCTOBER 13, 2022
In response to emailed questions, Alicia Jackson talked about her healthcare background and how the healthcare startup is responding to a shifting legal landscape for women’s health following the overturning of Roe v. Wade by the U.S. Supreme Court. .
Medgadget
OCTOBER 13, 2022
Scientists at the University of Birmingham in the UK have trialed Generative Design, a design approach that relies on machine learning and artificial intelligence, to create patient-specific knee implants. At present, knee implants are typically created in a limited range of sizes and shapes. While 3D printing has opened some scope for implants that are adapted to an individual’s orthopedic anatomy, few are created with other important variables in mind, such as the activity level of the patient
MedCity News
OCTOBER 13, 2022
Walgreens Boots Alliance recently announced it will acquire its remaining 45% stake in home care company CareCentrix for $392 million. The news follows CVS Health’s plans to acquire Signify Health. While retailers could prove beneficial to home health, it’s too early to tell, experts said.
PharmaVoice
OCTOBER 13, 2022
President Susan Sobolov discusses how the startup is building on the work of two powerhouse Yale scientists to advance candidates for viruses — and beyond.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
OCTOBER 13, 2022
A Relmada Therapeutics drug candidate for major depressive disorder failed a Phase 3 clinical trial, but the biotech isn’t giving up on its pill yet. It’s pinning its hopes on additional studies testing the therapy as an additional treatment alongside other depression drugs.
pharmaphorum
OCTOBER 13, 2022
Day 2 coverage: Click here to read Reuters: Pharma 2022 Day 1 overview. Click here or the image below to read Reuters: Pharma 2022 Live coverage. The post Reuters Pharma 2022 – Day 2 coverage appeared first on.
MedCity News
OCTOBER 13, 2022
GoodRx is arguably most well-known for its search platform that allows consumers to compare drug prices across different pharmacies. Now, it has launched a similar platform for healthcare providers. The new platform, called “Provider Mode,” is designed to help providers search for drug cost information while they are conducting appointments with their patients.
European Pharmaceutical Review
OCTOBER 13, 2022
Astellas will present results from a Phase III clinical study evaluating fezolinetant, an investigational oral, non-hormonal compound being studied to potentially treat vasomotor symptoms (VMS) associated with menopause. Fezolinetant is designed as a selective neurokinin 3 (NK3) receptor antagonist. The SKYLIGHT 4 trial results demonstrate the 52-week safety and tolerability of fezolinetant 30mg and 45mg administered once daily.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
MedCity News
OCTOBER 13, 2022
The law enacted by Congress in 2008, aims to remove insurance-related obstacles to mental health and substance use disorder treatment, but it hasn’t been enforced effectively and there is a lack of oversight.
PharmaVoice
OCTOBER 13, 2022
As the oral biologic market heats up, Rani Therapeutics is looking to dominate the field with its robotic pill for treatment of chronic conditions.
MedCity News
OCTOBER 13, 2022
While much of the world was quarantining and working from home during the Covid-19 pandemic, […].
pharmaphorum
OCTOBER 13, 2022
It is World Osteoporosis Day this month, and Ben Hargreaves takes a look at what treatment options look like for patients living with the disease. Osteoporosis is a condition that causes bones to become weak and fragile, making them more likely to break due to a fall or even something as minor as a sudden movement. The condition is the most common chronic bone disease, which is more often seen in the elderly population.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
European Pharmaceutical Review
OCTOBER 13, 2022
The National Institute for Health and Care Excellence (NICE) is set to work with five health technology assessment (HTA) bodies to find solutions to common challenges in the sector, such as working with regulators and evaluating digital health technologies. In addition to NICE, the bodies involved are: Canadian Agency for Drugs and Technologies in Health (CADTH).
pharmaphorum
OCTOBER 13, 2022
GSK’s vaccine against respiratory syncytial virus (RSV) is one of the top prospects in its pipeline, but also one with considerable competition, so needs strong data to support the programme. Thankfully for the company, it seems to be so. This morning, GSK revealed the results from its pivotal AReSVi-006 trial of the RSV shot – called RSVPreF3 OA – having said earlier this year that the study was positive.
MedCity News
OCTOBER 13, 2022
How can specialty practices most effectively engage undertreated and underserved patients while navigating rising rates of workforce shortages, burnout and the financial pressures that come with operating a practice during a pandemic?
Pharmaceutical Technology
OCTOBER 13, 2022
Oncotelic Therapeutics has received a contract from the US Biomedical Advanced Research and Development Authority (BARDA) to develop OT-101 to treat long-term effects of respiratory distress after Covid-19 infection. Under the contract, the company will collect the long-term clinical data from patients with Covid-19 in Peru and Argentina, where the C001-2020-01 trial was carried out.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
MedCity News
OCTOBER 13, 2022
Respiratory syncytial virus has no approved vaccines anywhere in the world, but the chase to bring the first one to the market is heating. GSK reported Phase 3 data that position it for regulatory submissions the pharma giant is planning for later this year. Pfizer is also on track to seek regulatory approvals for its RSV vaccine candidate.
PharmaTimes
OCTOBER 13, 2022
Agreement will be key to building a pan-European market access practice
pharmaphorum
OCTOBER 13, 2022
Bayer’s quest to revamp its drug discovery engine continues apace, with the company’s recently acquired Vividion subsidiary forging an alliance with Tavros Therapeutics, aimed at finding new drug targets and biomarkers in oncology. Bayer bought Vividion for $1.5 billion upfront last year, saying that the company would boost its ability to develop medicines against targets once considered “undruggable” The latest deal extends that effort, with Tavros tasked with using its
PharmaTimes
OCTOBER 13, 2022
Virus can be lethal to humans and its spread is likely to accelerate this winter
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Copyright Clearance Center
OCTOBER 13, 2022
The post Partnering Legal & Library to Empower Teams Across the Drug Development Pipeline appeared first on Copyright Clearance Center.
Pharmaceutical Technology
OCTOBER 13, 2022
Inceptor Bio has partnered with cell engineering technology company Avectas to improve CAR-T cell therapies’ development and manufacturing to treat solid tumours. Under the collaboration deal, Inceptor Bio will use the Solupore technology from Avectas instead of electroporation for engineering T cells to yield a healthier T cell. This non-viral technology is well suited to the CAR-T cell process of Inceptor Bio.
pharmaphorum
OCTOBER 13, 2022
Swedish digital health company Alex Therapeutics has reported encouraging results in a trial of a digital therapeutic (DTx) for anxiety in patients with the respiratory disease idiopathic pulmonary fibrosis (IPF). The cognitive behavioural therapy-based DTx – called Almee (formerly VP04) – is being developed in collaboration with Swedish drugmaker Vicore Pharma to see if it can reduce the psychological symptom burden in adults diagnosed with IPF , a debilitating and progressive disease with no c
Pharmaceutical Technology
OCTOBER 13, 2022
The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Colonis Pharma’s melatonin oral solution for the treatment of sleep-onset insomnia in children and adolescents with attention-deficit hyperactivity disorder (ADHD). The therapeutic is meant for youth with ADHD aged 6-17 years who found sleep hygiene measures inadequate.
Advertisement
The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.
Expert insights. Personalized for you.
137 
Let's personalize your content